OliX Updates Disclosure to Include FDA Application for Phase 2a OLX10212 Trial
Bitget2026/11/02 01:27- OliX Pharmaceuticals corrected its disclosure Nov. 2, 2026, to reflect an Oct. 31 FDA application for its Phase 2a OLX10212 trial.
- The trial targets 64 patients with bilateral age-related macular degeneration with geographic atrophy.
- US participation will include up to eight sites; the revised trial duration is approximately 35 months from approval, versus 38 months previously.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Crypto prices
More
